Stryker Corporation vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? Stryker Corporation trades at $285 (market cap $108.38B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.76 (market cap $1.26B). The key difference: Stryker Corporation is far larger — about 86× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Stryker Corporation pays a 1.25% dividend while Americas Gold and Silver Corporation Common Shares no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 22 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| SYK | USAS | |
|---|---|---|
Market Cap | $108.38B | $1.26B |
Volume | 2,068,363 | 3,948,671 |
Sector | Health | Basic Materials |
52-Week High | $388.35 | $10.03 |
52-Week Low | $269.75 | $3.59 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $119.84B | $1.19B |
Dividend Yield | 1.25% | — |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.
The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →